AFT Pharmaceuticals (ASX:AFP) has been granted approval from the US Food and Drug Administration for Maxigesic Rapid® tablets, a combination of 325mg paracetamol and 97.5mg ibuprofen that deploys a patented rapid release technology.
The approval opens an analgesic market for AFT in the US worth approximately US$7.16B and growing at a rate of 5.8% a year.
Maxigesic Oral Liquid, a combination of 160mg paracetamol and 48mg ibuprofen per 5ml oral suspension for children, has also received approval in 12 European countries.
AFT Pharmaceuticals is now looking at licensees and US market entry plans to maximise the commercial potential of Maxigesic.
The company also hopes that this medicine will be a useful therapeutic option to battle the opioid epidemic in the US.